Beta Glucan -The
risk of infectious disease is growing with the rise in
antibiotic-resistant infections, emerging infections, and bioterrorism.
Numerous preclinical and clinical studies support the efficacy of yeast
beta glucans to protect against a wide-variety of gram-positive and
gram-negative bacteria, antibiotic-resistant bacteria, fungal, parasitic
and viral infections. The basis for this anti-infective protective
effect is an enhancement of the innate immune system's ability to kill
these infectious agents, resulting in a 10-20 fold higher infectious
load to cause an infection in a preclinical rat model of infection.
Promising results have been obtained from animal studies with beta glucan to protect against for example, pneumonia, Escherichia coli, Staphylcoccus aureus, and sepsis. An important finding was that yeast Beta Glucan administration increased survival against antibiotic-resistant infections and that it acted synergistically with a wide-range of antibiotics (Figures 1 and 2).